https://orcid.org/0000-0003-2523-050X
References
- Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1–5. doi: 10.1056/NEJMra2023911.
- Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22(8):4130. doi: 10.3390/ijms22084130.
- Napolitano M, Fabbrocini G, Martora F, et al. Role of aryl hydrocarbon receptor activation in inflammatory chronic skin diseases. Cells. 2021;10(12):3559. doi: 10.3390/cells10123559.
- Mandlik DS, Mandlik SK. Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies. Immunopharmacol Immunotoxicol. 2021;43(2):105–125. doi: 10.1080/08923973.2021.1889583.
- Wollenberg A, Werfel T, Ring J, et al. Atopic dermatitis in children and adults—diagnosis and treatment. Dtsch Arztebl Int. 2023;120(13):224–234. doi: 10.3238/arztebl.m2023.0011.
- Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–282. doi: 10.1016/S0140-6736(22)01199-0.
- Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449. doi: 10.1111/bjd.19574.
- https://www.prnewswire.com/news-releases/subcutaneous-biologics-technologies-and-drug-delivery-systems-2nd-edition-2018-2030-300696232.html. (last access 2 August 2023)
- Thomaidou E, Ramot Y. Injection site reactions with the use of biological agents. Dermatol Ther. 2019;32(2):e12817. doi: 10.1111/dth.12817.
- Gast A, Mathes T. Medication adherence influencing factors-an (updated) overview of systematic reviews. Syst Rev. 2019;8(1):112. doi: 10.1186/s13643-019-1014-8.
- Eicher L, Knop M, Aszodi N, et al. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease - strategies for optimizing treatment outcome. J Eur Acad Dermatol Venereol. 2019;33(12):2253–2263. doi: 10.1111/jdv.15913.
- https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf. (last access 2 August 2023).
- Thaçi D, L Simpson E, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266–275. doi: 10.1016/j.jdermsci.2019.02.002.
- https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf. (last access 2 August 2023).
- Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450–463. doi: 10.1111/bjd.19573.
- De Greef A, Ghislain PD, Bulinckx A, et al. Real-Life experience of tralokinumab for the treatment of adult patients with severe atopic dermatitis: a multicentric prospective study. Clin Drug Investig. 2023;43(4):299–306. doi: 10.1007/s40261-023-01258-7.
- Pezzolo E, Schena D, Gambardella A, et al. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. J Eur Acad Dermatol Venereol. 2024;38(1):e11–e13. doi: 10.1111/jdv.19382.
- Gargiulo L, Ibba L, Vignoli CA, et al. Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. J Dermatolog Treat. 2023;34(1):2216815. doi: 10.1080/09546634.2023.2216815.
- Corominas M, Gastaminza G, Lobera T. Hypersensitivity reactions to biological drugs. J Investig Allergol Clin Immunol. 2014;24(4):212–225; quiz 1p following 225.
- Singh SK, Mahler HC, Hartman C, et al. Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants? J Pharm Sci. 2018;107(11):2735–2741. doi: 10.1016/j.xphs.2018.07.016.